There is no generic version of Breztri Aerosphere available right now. AstraZeneca holds patents on this triple-combination inhaler that extend through at least 2030, with some patents lasting until 2038. That means a generic equivalent is likely years away from reaching pharmacies.
Why No Generic Exists Yet
Breztri Aerosphere combines three active ingredients in a single pressurized metered-dose inhaler: an inhaled corticosteroid (budesonide, 160 mcg), a long-acting muscarinic antagonist (glycopyrrolate, 9 mcg), and a long-acting bronchodilator (formoterol fumarate, 4.8 mcg). Each puff delivers all three medications simultaneously to treat COPD.
Generic inhalers are harder to develop than generic pills. A manufacturer would need to replicate not just the drug formulation but also the delivery device, the particle size, and the way the medication deposits in the lungs. The FDA requires rigorous testing to confirm a generic inhaler performs equivalently. Combined with AstraZeneca’s patent portfolio, which covers the product in the U.S. through 2030 to 2038, these hurdles make a near-term generic unlikely.
What Breztri Costs Without a Generic Option
Without insurance, a smaller 5.9-gram Breztri inhaler runs about $400, while the larger 10.7-gram inhaler costs roughly $700. For people on Medicare Part D, coverage depends entirely on the specific plan’s formulary. Some plans cover it; others don’t, or they place it on a higher cost-sharing tier.
AstraZeneca offers a Zero Pay Program for commercially insured patients. If your insurance covers Breztri without prior authorization or step-edit restrictions, the savings card can reduce your copay to $0 per 30-day supply, up to a maximum annual limit. The catch: this program is not available to anyone enrolled in a state or federally funded insurance program, including Medicare, Medicaid, and TRICARE. You also can’t use it if you choose to pay cash while enrolled in one of those programs.
Trelegy Ellipta: The Closest Alternative
While there’s no generic Breztri, there is another single-inhaler triple therapy for COPD called Trelegy Ellipta. It contains a different corticosteroid (fluticasone furoate), a different muscarinic antagonist (umeclidinium), and a different long-acting bronchodilator (vilanterol). The practical differences come down to how you use them: Breztri is a pressurized metered-dose inhaler taken twice daily, while Trelegy is a dry-powder inhaler taken once daily.
Neither is a generic of the other since they contain entirely different active ingredients. But if cost or insurance coverage is the issue, your prescriber may be able to switch you to whichever one your plan covers at a lower tier. Some insurance formularies favor one over the other, so checking both options with your pharmacy can reveal meaningful savings.
Using Separate Inhalers Instead
Before single-inhaler triple therapies existed, doctors prescribed the same three drug classes as two or three separate inhalers. Some of those individual components are available as generics or at lower cost. For example, generic budesonide inhalers exist, and some two-drug combination inhalers have been on the market long enough to have more competitive pricing.
The tradeoff is convenience and adherence. Juggling multiple inhalers with different dosing schedules increases the chance of missed doses. Studies suggest that delivering all three medications simultaneously may improve how consistently people use their treatment, which directly affects symptom control. Still, if Breztri’s price is a barrier, separate inhalers prescribed together can deliver the same drug classes to your lungs.
What to Expect Going Forward
The earliest any U.S. patent on Breztri expires is 2030, but additional patents could block generic competition until 2038. Even after patents expire, developing and gaining FDA approval for a generic inhaler typically takes several additional years. Realistically, a true generic Breztri is not expected before the early 2030s at the soonest.
In the meantime, your best options for managing costs are the AstraZeneca savings card (if you have commercial insurance), checking whether Trelegy Ellipta has better formulary placement on your plan, or discussing separate-inhaler alternatives with your prescriber.